Exocrine Pancreatic Insufficiency Market Research Report By Disease Type (Chronic Pancreatitis, Pancreatic Cancer, Cystic Fibrosis, Shwachman-Diamond Syndrome, Other Rare Conditions), By Treatment Type (Enzyme Replacement Therapy (ERT), Pancreatic Enzyme Supplements, Other Therapies (Insulin Therapy, Anti-Inflammatory Drugs, Surgery)), By Dosage Form (Capsules, Tablets, Powders, Granules), By Administration Route (Oral, Intravenous, Subcutaneous), By End User (Hospitals & Clinics, Home Healthcare Settings, Pharmacies & Retail Stores) and By

Exocrine Pancreatic Insufficiency Market Overview

As per MRFR analysis, the Exocrine Pancreatic Insufficiency Market Size was estimated at 2.7 (USD Billion) in 2022. The Exocrine Pancreatic Insufficiency Market Industry is expected to grow from 2.85 (USD Billion) in 2023 to 4.6 (USD Billion) by 2032. The Exocrine Pancreatic Insufficiency Market CAGR (growth rate) is expected to be around 5.48% during the forecast period (2024 - 2032).

Key Exocrine Pancreatic Insufficiency Market Trends Highlighted

Key Market Drivers:The rise in incidences of chronic pancreatitis and cystic fibrosis, coupled with the increasing prevalence of digestive disorders, fuels the demand for exocrine pancreatic insufficiency treatment options. Advanced technologies and novel drug delivery systems offer effective solutions, driving market growth.Opportunities to be Explored:Emerging markets in Asia-Pacific and Latin America present lucrative opportunities due to rising healthcare expenditure and unmet medical needs. The development of precision medicine and personalized treatment approaches tailored to individual patient profiles offers untapped potential.Trends in Recent Times:The integration of artificial intelligence (AI) and machine learning in exocrine pancreatic insufficiency management enhances diagnosis accuracy and treatment optimization. The advent of minimally invasive surgical procedures and endoscopic techniques reduces patient discomfort and recovery time. Research into gene therapy and stem cell therapies holds promise for addressing the underlying causes of pancreatic insufficiency.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Market Drivers

Rising Prevalence of Chronic Pancreatitis

One of the primary drivers of significant growth in the global EPI market will be the increased prevalence of chronic pancreatitis as a leading cause of exocrine pancreatic insufficiency, which appears to become more widespread due to the increasing share of related risk factors in the global burden of disease. Alcohol abuse, obesity, and smoking are the most prominent risk factors for chronic pancreatitis, and the increased incidence of these issues will be driving greater EPI prevalence in the future.The higher prevalence of the leading cause of exocrine pancreatic insufficiency correlates with the general trend in greater EPI incidence, which will create a much larger market for existing and new treatment options. This trend is particularly relevant in the context of developing countries, where the prevalence of the leading risk factors for chronic pancreatitis is expected to increase due to further availability and promotion of these habits that coincide with relatively low access to care and other resources.Consequently, the current market suffers from a notable gap in terms of the capacity to monitor and manage exocrine pancreatic insufficiency in emerging regions. Overall, the strengthened necessity and the increased feasibility of treating chronic pancreatitis and EPIs symptoms will continue to drive the development of new options in the global EPI market. In practice, the current area of greatest needs, as identified by the existing market players, includes enzyme replacement options, which is one of the main drivers for the continued increased availability of existing and new options.

Increasing Awareness and Diagnosis of EPI

Exocrine pancreatic insufficiency is a condition that may be challenging to diagnose as its symptoms may be indicative of numerous digestive disorders. In recent years, the diagnostic rates for EPI have started to increase and positively affect the global EPI market. One of the reasons for this is the wider acceptance of the condition, its manifesting symptoms, and the implementation of various, more accurate, and more accessible tests and screening in high-risk groups.There is an increasing awareness of the condition among both the affected people and clinicians, which prompts higher rates of diagnosis. Since more people are diagnosed with EPI, there is an increased demand for various treatment options, such as enzyme replacement therapy or dietary approaches. In turn, the increasing demand for treatment affects the development of new, more effective, or more usable products designed to treat EPI.

Growing Demand for Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy (ERT) is the mainstay of treatment for exocrine pancreatic insufficiency (EPI). ERT involves taking pancreatic enzyme supplements to help the body digest food. The growing demand for ERT is a major driver of growth in the global EPI market. There are a number of factors contributing to the growing demand for ERT. First, the prevalence of EPI is increasing, as discussed in the previous section. Second, there is a growing awareness of ERT and its benefits.Third, ERT is becoming more affordable and accessible. As a result of these factors, the demand for ERT is expected to continue to grow in the coming years.

Exocrine Pancreatic Insufficiency Market Segment Insights

Exocrine Pancreatic Insufficiency Market Disease Type Insights

In 2023, the chronic pancreatitis segment accounted for the highest market share of the Exocrine Pancreatic Insufficiency Market and is anticipated to dominate the market during the forecast period. This is mainly attributed to the high incidence of chronic pancreatitis due to the increasing prevalence of obesity and alcohol intake. The second largest segment of the Exocrine Pancreatic Insufficiency Market is pancreatic cancer; this is mainly driven by the increasing incidence of pancreatic cancer, and due to the lack of proper medications, the prescription base for EPI available in the market is limited.Cystic fibrosis is a particularly rare genetic disorder that affects mostly exocrine glands such as the pancreas. The factors responsible for the growth of this segment are the increasing incidence of cystic fibrosis and the rise in demand for advanced treatments. Shwachman-Diamond syndrome is also a rare disease that mostly affects the bone marrow and other exocrine glands, such as the pancreas. The factors responsible for the development of this segment are increasing awareness about the Shwachman-Diamond syndrome and rising demand for the different medications for the treatment of this disease.Autoimmune pancreatitis and tropical pancreatitis are the other rare diseases responsible for the boost in the growth of the Exocrine Pancreatic Insufficiency Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Market Treatment Type Insights

Enzyme Replacement Therapy (ERT) dominates the Exocrine Pancreatic Insufficiency Market revenue, accounting for a significant market share in 2023. ERT involves administering pancreatic enzymes to aid digestion. Its efficacy in managing symptoms and improving nutrient absorption drives market growth. Pancreatic enzyme supplements, another treatment option, offer a convenient and cost-effective alternative to ERT. Other therapies, including insulin therapy, anti-inflammatory drugs, and surgery, address specific aspects of the condition. Surgery, for instance, may be necessary to remove blockages or tumors in the pancreas.The Exocrine Pancreatic Insufficiency Market segmentation provides insights into the relative performance of these treatment types, enabling stakeholders to optimize product development and marketing strategies.

Exocrine Pancreatic Insufficiency Market Dosage Form Insights

The Exocrine Pancreatic Insufficiency Market is segmented into Capsules, Tablets, Powders, and Granules based on Dosage Form. Among these, the Tablets segment held the largest market share in 2023, accounting for around 48.5% of the Exocrine Pancreatic Insufficiency Market revenue. This is due to the ease of administration and the availability of various strengths and formulations of tablets. The Capsules segment is also expected to witness significant growth during the forecast period, owing to factors such as the growing preference for convenient dosage forms.The Powders and Granules segments are expected to have a moderate growth rate, as they are preferred by patients who have difficulty swallowing tablets or capsules. Overall, the Exocrine Pancreatic Insufficiency Market is expected to witness steady growth over the forecast period, driven by the increasing prevalence of chronic pancreatitis and other exocrine pancreatic disorders.

Exocrine Pancreatic Insufficiency Market Administration Route Insights

The Exocrine Pancreatic Insufficiency Market is segmented based on Administration Route into Oral, Intravenous, and Subcutaneous. Among these, the Oral segment is expected to hold the largest market share in 2023 and is projected to continue its dominance throughout the forecast period, owing to the ease of administration and better patient compliance associated with oral medications. The Intravenous segment is expected to account for a significant share of the market, primarily due to the rapid onset of action and the ability to deliver high doses of medication.The Subcutaneous segment is expected to witness a steady growth rate during the forecast period, driven by the increasing adoption of subcutaneous formulations for patients who are unable to tolerate oral or intravenous medications.

Exocrine Pancreatic Insufficiency Market End User Insights

Hospitals Clinics held the largest share of the Exocrine Pancreatic Insufficiency Market in 2023, and this trend is expected to continue over the forecast period. The large number of patients diagnosed with exocrine pancreatic insufficiency who require specialized care and the availability of advanced diagnostic and therapeutic facilities in hospitals and clinics drive this segment's growth. The increasing prevalence of chronic pancreatitis, which is a major cause of exocrine pancreatic insufficiency, is also contributing to the growth of this segment.Home Healthcare Settings are expected to witness significant growth during the forecast period. The increasing demand for home healthcare services due to the rising number of patients with chronic conditions and the growing preference for home-based care are driving the growth of this segment. The availability of portable and easy-to-use devices for administering pancreatic enzyme replacement therapy (PERT) is also contributing to the growth of this segment. Pharmacies Retail Stores are expected to hold a moderate share of the Exocrine Pancreatic Insufficiency Market.The increasing availability of over-the-counter (OTC) PERT products and the growing awareness of exocrine pancreatic insufficiency among patients are driving the growth of this segment. The presence of well-established distribution channels and the convenience of purchasing PERT products from pharmacies and retail stores are also contributing to the growth of this segment.

Exocrine Pancreatic Insufficiency Market Regional Insights

Regionally, North America held the largest market share in 2023, accounting for over 40% of the global revenue. The region's dominance can be attributed to the high prevalence of chronic pancreatitis, cystic fibrosis, and other conditions that lead to exocrine pancreatic insufficiency. Europe and APAC are also significant markets, with Europe expected to witness a steady growth rate due to increasing awareness and diagnosis of the condition. South America and MEA are anticipated to show promising growth potential, driven by rising healthcare expenditure and improving healthcare infrastructure.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Market Key Players And Competitive Insights:

The Exocrine Pancreatic Insufficiency Market industry’s major players are focused on developing new and innovative product offerings to cater to the needs of patients. Leading players in the Exocrine Pancreatic Insufficiency Market are channeling their investments into research and development to enhance the efficacy and safety of their product offerings. The Exocrine Pancreatic Insufficiency Market is projected to soon record an emerging phase as the incidence of chronic pancreatitis and other diseases causing exocrine pancreatic insufficiency rises. The Exocrine Pancreatic Insufficiency Market’s competitive landscape is characterized by a medium level of fragmentation, with a large number of small and medium-sized players present in the market. Nonetheless, the market for exocrine pancreatic insufficiency is expected to witness consolidation in the coming years as larger players acquire smaller players to achieve a better market standing.AbbVie is a major player in the Exocrine Pancreatic Insufficiency Market, with key products including Creon and Pancreaze for the treatment of exocrine pancreatic insufficiency. AbbVie is also involved in research and development to enhance the safety and efficacy profile of its product offerings. The company is also expanding its international presence through a healthy mix of acquisitions and partnerships. Shire is another prominent player in the Exocrine Pancreatic Insufficiency Market, with significant products including Pancrease and Kudel. Shire is involved in research and development to improve the safety and efficacy of product offerings and is also expanding its international presence through acquisitions and partnerships.The competitor company in the Exocrine Pancreatic Insufficiency Market is Eli Lilly, with premium product offerings, including Zenpep for the treatment of pancreatic exocrine insufficiency. Eli Lilly is focusing on research and development to develop enhanced safety and efficacy profiles of its product and is expanding its international presence through a healthy mix of acquisitions and partnerships. Eli Lilly is a major player in the Exocrine Pancreatic Insufficiency Market and is also expected to grow in the near future.

Key Companies in the Exocrine Pancreatic Insufficiency Market Include

• Roche


• Mylan


• Merck Co


• Shire Plc


• Hikma


• AbbVie


• Reddy's Laboratories


• Zydus Cadila


• Novo Nordisk


• Pfizer


• Baxter


• Fresenius


• Akorn


• Eli Lilly


• Johnson Johnson

Exocrine Pancreatic Insufficiency Market Industry Developments

New Product Launches: Several pharmaceutical companies have launched new enzyme replacement therapies (ERTs) in recent years, offering improved efficacy and convenience for patients. For instance, in 2023, AbbVie introduced Trilipix, a novel ERT that combines three pancreatic enzymes in a single capsule.Strategic Partnerships: Collaborations between pharmaceutical companies and patient advocacy groups are on the rise, aiming to enhance patient access to ERTs and support research and development efforts. In 2022, the Pancreatic Cancer Action Network partnered with AbbVie to launch a program providing financial assistance to patients with EPI.Market Expansion: The EPI market is expanding geographically, with emerging regions such as Asia-Pacific and Latin America experiencing significant growth. This is driven by increasing awareness of EPI, improved healthcare infrastructure, and rising disposable incomes.These developments indicate a growing focus on improving patient outcomes and expanding access to treatment for EPI, which is expected to continue driving market growth in the coming years.

Exocrine Pancreatic Insufficiency Market Segmentation Insights

Exocrine Pancreatic Insufficiency Market Disease Type Outlook

• Chronic Pancreatitis


• Pancreatic Cancer


• Cystic Fibrosis


• Shwachman-Diamond Syndrome


• Other Rare Conditions

Exocrine Pancreatic Insufficiency Market Treatment Type Outlook

• Enzyme Replacement Therapy (ERT)


• Pancreatic Enzyme Supplements


• Other Therapies (Insulin Therapy, Anti-Inflammatory Drugs, Surgery)

Exocrine Pancreatic Insufficiency Market Dosage Form Outlook

• Capsules


• Tablets


• Powders


• Granules

Exocrine Pancreatic Insufficiency Market Administration Route Outlook

• Oral


• Intravenous


• Subcutaneous

Exocrine Pancreatic Insufficiency Market End User Outlook

• Hospitals Clinics


• Home Healthcare Settings


• Pharmacies Retail Stores

Exocrine Pancreatic Insufficiency Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa